Escaline

The current DEA schedule-by-schedule table expressly places Escaline in the positional-isomer parenthetical under Schedule I 3,4,5-trimethoxyamphetamine (TMA), CSCN 7390, and the current eCFR text supplies the Schedule I hallucinogen/isomer framework and the TMA entry. PubChem identifies the exact Escaline identity as 2-(4-ethoxy-3,5-dimethoxyphenyl)ethanamine, formula C12H19NO3, CAS RN 39201-82-6. The classification applies only to a substance actually matching that identity; a court-specific dispute could concern sample identity, mixture/salt characterization, or the legal construction of the DEA table's parenthetical designation. The Federal Analogue Act provides a bounded alternative or overlapping basis: 21 U.S.C. § 802(32) requires substantially similar structure to a Schedule I or II substance plus substantially similar or greater CNS effect, or a particular person's representation/intention of such effect, subject to exclusions including approved drugs and the extent not intended for human consumption. Under § 813, a qualifying analogue is treated as Schedule I only to the extent intended for human consumption; marketing, labeling, usefulness, price, diversion, known intended means of consumption and evasion evidence may be considered, and a non-human-consumption label alone is insufficient. Accordingly, every transaction or every sample is not necessarily prosecutable: unauthorized knowing or intentional manufacture, distribution, dispensing or possession with intent is addressed by § 841(a), simple possession by § 844(a), and attempts/conspiracies by § 846, each subject to statutory elements and exceptions. For a Schedule I/II substance, § 841(b)(1)(C) provides up to 20 years (up to 30 years after a prior felony drug conviction, with enhanced death/serious-bodily-injury provisions and fines); § 844(a) provides up to 1 year and a minimum $1,000 fine for a first simple-possession offense, with higher repeat-offense ranges and minimum fines. The U.S. Code text is in effect August 27, 2026; the eCFR text is dated August 26, 2026; and the DEA schedules identify the Orange Book as August 2026.

PubChem identifies Escaline as a 2-phenylethan-1-amine derivative with a phenyl ring bearing 3,5-dimethoxy and 4-ethoxy substituents, an unsubstituted 2-aminoethyl side chain, and molecular weight 225.28 u. Anlage 1 no. 1 covers chemical compounds derivable from a 2-phenylethan-1-amine base (other than 2-phenethylamine itself), up to 500 u; section 1.1 permits phenyl substitution by alkoxy groups up to C7, and section 1.2 permits the 2-aminoethyl side-chain substitutions. Escaline therefore falls within the generic NpSG group. Its classification is based on the published definition rather than an express Escaline listing or a case-specific judicial ruling; material sold under that name must still match the described structure and relevant covered form. NpSG § 3(1) no. 1 prohibits trade, placing into circulation, manufacture, import/export/transit, acquisition, possession and administration to another, subject to the statutory recognised commercial, industrial, scientific and official-use exceptions in § 3(2). § 4 separately specifies criminal liability: up to three years or a fine for trade, placing into circulation, administration, or manufacture/import for placing into circulation; attempt is punishable; aggravated cases carry one to ten years (three months to five years in less serious cases), with separate negligence provisions. Simple acquisition or possession is prohibited by § 3 but is not itself listed as a standalone § 4 offence. The official consolidated NpSG page states its last amendment was 7 January 2026, and the Anlage 1 page identifies the current source as BGBl. 2025 I No. 292. The official BtMG Anlagen I–III contain no exact Escaline name or exact PubChem IUPAC entry; absence from those name lists does not establish structural absence because the NpSG generic group independently supplies the operative classification.

Designation: Class A controlled drug under the generic phenethylamine-derivative entry in Misuse of Drugs Act 1971 Schedule 2 Part I paragraph 1(c), because Escaline is 4-ethoxy-3,5-dimethoxyphenethylamine and has ring alkoxy substituents. Sections 3, 4 and 5 prohibit unauthorized import/export, production or supply, and possession, respectively, subject to the Act's licensing, regulation and other statutory qualifications; section 7 is the authorization framework. The Psychoactive Substances Act 2016 Schedule 1 paragraph 1 exempts controlled drugs, so the former PSA-only basis is removed.

Designated as a controlled substance under Japanese drug laws effective December 21, 2016.

The binding Fedlex consolidation is expressly dated/operative as of 13 March 2026 and names Escalin at Annex 6, item 147. BetmVV-EDI Article 1(2)(a)-(d) extends the listed substance coverage to specified salts, esters, ethers, carbamates, stereoisomers and preparations; the Swissmedic supplementary list records the free-base and hydrochloride CAS numbers. BetmKV Article 3(2)(e) defines Verzeichnis e as raw materials and products with presumed narcotic-like effects under BetmG Article 7(1), subject to the control measures for Verzeichnis-a narcotics; Article 5(2) assigns the operating permit for Verzeichnis-e substances to the EDI, and Article 11(1) requires an operating permit for specified handling. BetmG Article 7(1) requires EDI authorization for cultivation, manufacture, import/export, storage, use or placing such substances into circulation. BetmG Article 20(1)(c) provides up to three years' imprisonment or a monetary penalty for specified unauthorized handling of Article 7 substances. The Federal Supreme Court explains that Article 7 substances are not themselves Betäubungsmittel or psychotropic substances, so acquisition and consumption are not criminal under Art. 19a e contrario, while unauthorized manufacture, import/export, storage, use or placing into circulation is punishable under Art. 20(1)(c). Verzeichnis d is a separate prohibited category. Swissmedic's official 13 March 2026 notice confirms that EDI supplemented BetmVV-EDI on that date and that Verzeichnis e then comprised 320 substances/groups.